Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma

Area of Science:

• Hematology
• Oncology
• Lymphoma Research

Background:

• Peripheral T-cell lymphomas (PTCL) generally present with a poor prognosis, unlike anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).
• Current first-line chemotherapy often involves a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like regimen, with potential benefit from etoposide addition in younger patients.
• High relapse rates persist even after initial treatment response, and the role of autologous transplant in first remission remains uncertain, possibly benefiting only low-risk patients.

Purpose of the Study:

• To review the current treatment landscape for Peripheral T-cell lymphomas (PTCL).
• To highlight recent therapeutic advances in the relapsed/refractory setting.
• To identify the unmet needs in PTCL treatment.

Main Methods:

• Review of current clinical practice guidelines and literature.
• Analysis of recent drug approvals for relapsed/refractory PTCL.
• Discussion of treatment outcomes and prognostic factors.

Main Results:

• Four new agents (pralatrexate, romidepsin, belinostat, brentuximab vedotin) have been FDA-approved for relapsed/refractory PTCL since 2009.
• Brentuximab vedotin is expected to significantly alter treatment approaches for ALCL.
• Despite these advances, many PTCL patients still lack effective treatment options.

Conclusions:

• Significant progress has been made in treating relapsed/refractory PTCL with newly approved agents.
• Further research and development are crucial to address the needs of patients with PTCL for whom current therapies are ineffective.
• Tailored treatment strategies, especially for ALCL, are evolving.